LC
KRYS icon

Lindbrook Capital’s Krystal Biotech KRYS Stock Holding History

Lindbrook Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$9.2K Sell
51
-7
-12% -$1.18K ﹤0.01% 1692
2024
Q4 		$9.09K Sell
58
-20
-26% -$3.55K ﹤0.01% 1700
2024
Q3 		$14.2K Buy
78
+3
+4% +$578 ﹤0.01% 1492
2024
Q2 		$13.8K Buy
75
+38
+103% +$6.38K ﹤0.01% 1455
2024
Q1 		$6.58K Buy
37
+1
+3% +$139 ﹤0.01% 1772
2023
Q4 		$4.47K Sell
36
-2
-5% -$222 ﹤0.01% 1943
2023
Q3 		$4.41K Buy
38
+6
+19% +$732 ﹤0.01% 1824
2023
Q2 		$3.76K Hold
32
– – ﹤0.01% 1926
2023
Q1 		$2.56K Sell
32
-19
-37% -$1.49K ﹤0.01% 2140
2022
Q4 		$4.04K Buy
51
+41
+410% +$3.04K ﹤0.01% 1929
2022
Q3 		$1K Buy
10
+5
+100% +$361 ﹤0.01% 2380
2022
Q2 		$0 Sell
5
-7
-58% -$435 ﹤0.01% 2629
2022
Q1 		$1K Buy
+12
New +$749 ﹤0.01% 2274
2020
Q2 		– Sell
-25
Closed -$1K – 1804
2020
Q1 		$1K Buy
25
+6
+32% +$314 ﹤0.01% 1489
2019
Q4 		$1K Buy
+19
New +$932 ﹤0.01% 1409

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Lindbrook Capital's KRYS Position: Q1 2025 in Review

Lindbrook Capital reduced its Krystal Biotech (KRYS) stake by 12% in Q1 2025, selling an estimated $1.18K and leaving 51 shares worth $9.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

Lindbrook Capital first reported a position in KRYS in Q4 2019 and has held it in 15 quarters since. The position peaked at $14.2K in Q3 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Lindbrook Capital held 51 shares of Krystal Biotech worth $9.2K as of Q1 2025.
  • Lindbrook Capital sold 7 Krystal Biotech shares in Q1 2025, an estimated $1.18K.
  • Krystal Biotech made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1692 holding.
  • Lindbrook Capital first reported a position in Krystal Biotech in Q4 2019 and has held it in 15 quarters since.
  • Lindbrook Capital's Krystal Biotech position peaked at $14.2K in Q3 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.